

REVIEW ARTICLE

Complications and treatment errors in periodontal therapy in medically compromised patients

Yago Leira^{1,2,3}  | Hana Cho⁴ | Debora Marletta⁵ | Marco Orlandi¹ | Pedro Diz⁶ | Navdeep Kumar⁴ | Francesco D'Aiuto¹

¹Periodontology Unit, UCL Eastman Dental Institute & NIHR UCLH Biomedical Research Centre, University College London, London, UK

²Periodontology Unit, Faculty of Odontology, University of Santiago de Compostela & Medical-Surgical Dentistry Research Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain

³Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain

⁴Special Care Dentistry Unit, ENT & Eastman Dental Hospital, UCLH NHS Foundation Trust, London, UK

⁵UCL Library Services, University College London, London, UK

⁶Special Care Dentistry Unit, Faculty of Odontology, University of Santiago de Compostela & Medical-Surgical Dentistry Research Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain

Correspondence

Francesco D'Aiuto, Periodontology Unit, UCL Eastman Dental Institute, 21 University Street, London WC1E 6DE, UK.

Email: f.daiuto@ucl.ac.uk

Funding information

National Institute for Health Research; UCL Biomedical Research Centre, Grant/Award Number: NIHR-INF-0387

1 | INTRODUCTION

In 2019, worldwide life expectancy was estimated at approximately 72 years of age. This has improved dramatically over decades, and is mirrored in childhood survival rates.¹ As a consequence, the number of people presenting with long-term conditions is increasing rapidly, as it is closely related to aging.² Multimorbidity in this aging population is common and it has been rising in prevalence over recent years, with one in three adults living with more than one chronic disease.^{3,4}

Evidence on the prevalence of systemic diseases in patients presenting for periodontal care suggests that between 40% and 52% of patients have more than one systemic condition, and these estimates increase with age.⁵⁻⁷ In addition, the type of medical problems patients present with can differ significantly depending upon the facility where periodontal care is provided.⁸ Findings from a retrospective analysis demonstrated a lower prevalence of medically compromised patients with periodontitis who attended a private dental practice (28%) compared with those attending a dental school or hospital clinic (46% and 74%, respectively).⁸ Differences between

participants in terms of age, socioeconomic status, or health awareness could explain these findings.⁸ The most frequently reported medical problems in the dental office are allergies to medications followed by cardiovascular diseases (including hypertension) and endocrine disorders (including diabetes mellitus).⁵⁻¹⁰

As a direct consequence of medical comorbidities, a substantial number of patients will be taking multiple medications, which may also have an impact on their periodontal management. Radfar and Suresh¹¹ observed that of 1041 patients treated in their dental school, 360 (35%) were taking antihypertensives, 202 (19%) painkillers, 181 (17%) antidepressants, 107 (10%) antidyslipidemic agents, and 95 (9%) antiplatelet drugs. This highlights an additional consideration in terms of the potential pharmacologic interactions with anesthetics or other medications that we might need to prescribe for these patients after certain periodontal procedures.

In addition to the systemic pathology inherent to age and polypharmacy, the increased survival of patients with certain congenital diseases with periodontal manifestations has created a growing demand for periodontal treatment. These congenital disorders include

Yago Leira contributed equally to the manuscript.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. *Periodontology 2000* published by John Wiley & Sons Ltd.

diseases with a considerable prevalence such as Down syndrome¹² and around 14% of rare disorders with a low prevalence.¹³ The provision of dental treatment for these patients is not exempt from some potential complications, because the etiopathogenic mechanisms of these diseases include hemorrhagic diatheses, immunodeficiencies, and alterations in the metabolism of vitamins, minerals, and trace elements.¹³

Treatment of periodontitis is part of routine care of patients attending dental practices, but it may be associated with complications, particularly when invasive/surgical approaches are required. Although the overall incidence of these complications is low, it includes prolonged bleeding (1%-8%),¹⁴⁻¹⁷ infection (1%-4%),^{14-16,18-20} swelling (1%-60%),¹⁴⁻¹⁶ pain (4%-49%),¹⁴⁻¹⁷ and delayed wound healing (2.5%).¹⁴ In some lower number of cases, complications linked to specific surgical procedures may occur, such as membrane barrier exposure, flap dehiscence, or graft (soft or hard tissue-derived) necrosis.¹⁴ The variability of complication rates is strictly dependent upon the periodontal procedure performed.^{14,16} Askar et al¹⁴ retrospectively evaluated complication rates of different periodontal procedures and found that patients who received osseous surgery more frequently developed some type of complication (in 25% of cases), followed by free gingival graft technique (20%), crown lengthening (16%), guided tissue regeneration (13%), open flap debridement (12%), and connective tissue graft procedures (10%). Gingivectomy appeared to be the surgical periodontal technique with the lowest rate of complications (5%).¹⁴

The presence of any long-term condition may increase the risk of having a complication during or after treatment of periodontitis, as evidenced by Askar et al,¹⁴ who reported that patients diagnosed with diabetes mellitus were six and 25 times more likely to experience delayed wound healing after an open flap debridement procedure and mucogingival surgery, respectively.

The aim of this narrative review is to provide a comprehensive overview of the potential complications and treatment errors that can occur in medically compromised patients undergoing both non-surgical and surgical treatment of periodontitis. Specific risk reduction strategies for these patients are also discussed.

2 | EVIDENCE SEARCH METHODOLOGY

To gather all the evidence published in relation to complications after periodontal treatment in medically compromised patients, a systematic search in Medline OvidSP was carried out from 1946 to 10 July 2020. Three key searchable concepts were identified: "Periodontal Diseases", "Surgical and Non-Surgical Periodontal Therapies", and "Systemic Diseases". Given the broad scope of the concept "Medically Compromised Patients", a list of all diseases to be included in the review was compiled at the protocol stage and search strategies were created for each disease to be appended to a search including the first two concepts.

We conducted searches for each concept using text word terms and medical subject headings wherever these were available. When

we carried out text word searches, synonyms, related terms, and singular/plural forms for each concept were used. This strategy ensured that we retrieved studies where surgical and nonsurgical periodontal therapies for periodontal diseases (including dental extractions as part of the periodontal treatment) were discussed along with each systemic disease of interest. We exported the results for each search to the reference management software Endnote X9, which we used to manage our references. We applied no language or date restrictions and used the high-sensitivity animal filter for Medline OvidSP (exp animals/not humans.sh), which we combined with our search strategy with the use of the Boolean operator NOT to exclude animal studies. No restriction was made in terms of study design (ie, from case reports to randomized clinical trials).

The total number of records retrieved by the electronic database was 9294, and one additional article was obtained via a manual search. After removing duplicates, we screened 6599 titles/abstracts and selected 112 articles for full-text screening. Finally, we chose 20 articles to be included in this narrative review.

3 | COMPLICATIONS AFTER PERIODONTAL THERAPY IN PATIENTS WITH COMORBIDITIES

Most studies reported different complications following nonsurgical and surgical periodontal procedures in medically compromised patients (Table 1). Most of the studies included were case reports.²¹⁻³² Two publications were case series,^{33,34} four studies had a cross-sectional design,³⁵⁻³⁸ and only two were randomized controlled clinical trials.^{39,40} The type of complication reported was related to the modality of periodontal treatment and the patient's systemic condition. In most of the studies, a low complication rate was observed (~5%). The most frequently reported complication was bleeding in more than half of the studies included in this review.^{22,23,25,26,29-33,35-38,40} Other less common oral complications include delayed wound healing,^{21,22} barrier membrane exposure,^{27,28} infection,^{28,39} and medication-related osteonecrosis of the jaw.²⁴

3.1 | Bleeding-related complications

Four different groups of patients could be identified when prolonged gingival bleeding was reported as a complication after periodontal treatment: in patients with bleeding disorders, drug-induced gingival overgrowth, those taking antithrombotic medications, and patients with hypertension.

3.1.1 | Bleeding disorders

Bleeding disorders can be congenital or acquired (Table 2). An in-depth review of their relationship with periodontics has been previously published and it is not within the scope of the current review.⁴¹

TABLE 1 Summary of publications reporting on complications related to periodontal therapy in medically compromised patients

Authors (year)	Country	Study design	Systemic condition	Intervention	Complication	Complication rate	Complication management
Andersen et al. (2003) ²¹	Norway	Case report	Crohn's disease	Mucogingival surgery (coronally advanced flap with or without enamel matrix derivative)	Altered and delayed healing	—	0.2% clorhexidine mouthwash + 1% clorhexidine gel (once/d for 3 wk)
Blanco-Carrion et al. (2004) ²²	Spain	Case report	Moderate hemophilia A, HIV infection (B ₂ stage), and chronic hepatitis C	Mucogingival surgery (subepithelial connective tissue graft)	Area of necrosis at donor palatal site with spontaneous bleeding 1 wk after procedure	—	Factor VIII concentrate (2500 units twice/d, during 1 wk) + prophylactic Factor VIII concentrate (2500 units once/2 d, for 2 more wk)
Campo et al. (2007) ³⁵	Spain	Cross-sectional	HIV infection	a. Dental prophylaxis (n = 33) b. Scaling and root planing (n = 8) c. Surgical therapy (n = 3)	a. None b. Prolonged gingival bleeding c. None	a. 0.0% (0/45) b. 5.8% (1/17) c. 0.0% (0/4)	Not reported
Cutler et al. (1991) ²³	USA	Case report	Type 1 diabetes mellitus	Nonsurgical periodontal treatment (scaling and root planing) + dental extractions	Liver clots without clot retraction for up to 10 d postextractions	—	Not reported
D'Aiuto et al. (2018) ³⁹	UK	Randomized controlled clinical trial (intensive periodontal therapy vs control periodontal therapy)	Type 2 diabetes mellitus	a. Intensive periodontal therapy (scaling and root planing + re-instrumentation or modified Widman flap technique) (n = 133) b. Control periodontal therapy (supragingival scaling and polishing) (n = 131)	a. Oral: tooth pain, tooth sensitivity, tooth infection, tooth fracture, tooth restoration and gum swelling b. Systemic: chest infection, headache, influenza, throat infection, foot infection, fainting, dizziness, and back pain	a. Dental pain (4%), sensitivity (3.1%), infection (2.5%), fracture (1.1%), restoration (0.8%), gum swelling (1.1%), chest infection (1.2%), headache (0.8%), influenza (0.7%), throat infection (0.4%), foot infection (0.5%), fainting (0.3%), dizziness (0.4%) and back pain (0.3%) b. Dental pain (3.0%), sensitivity (0.9%), infection (2.6%), fracture (1.6%), restoration (1.1%), gum swelling (0.8%), chest infection (1.0%), headache (0.4%), influenza (0.7%), throat infection (0.5%), foot infection (0.6%), fainting (0.3%), dizziness (0.4%) and back pain (0.5%)	Not reported

(Continues)

TABLE 1 (Continued)

Authors (year)	Country	Study design	Systemic condition	Intervention	Complication	Complication rate	Complication management
Diniz-Freitas et al. (2018) ²⁴	Spain	Case report	Osteoporosis treated with biannual subcutaneous injections of 60 mg of denosumab	Nonsurgical periodontal treatment (scaling and root planing)	Medication-related osteonecrosis of the jaw (stage I)	—	Extraction of teeth involved in the sequestration + complete surgical debridement of necrotic bone + 0.2% chlorhexidine mouthwash (2/d) and doxycycline (200 mg/d) from the 7 d prior to surgery until 3 wk postsurgery
Deppe et al. (2013) ³⁶	Germany	Cross-sectional	Prosthetic heart valve surgery <i>Relevant medication: anticoagulant coumarin drug</i>	a. Periodontal surgery (modified Widman flap technique) with the use of Nd:YAG laser + dental extractions (n = 24) b. Periodontal surgery (modified Widman flap technique) without the use of Nd:YAG laser + dental extractions (n = 21)	Gingival bleeding within 24 h after postoperative hemostasis	a. 3.7% (2/53) b. 4.5% (2/44)	Local hemostasis with either Nd:YAG laser or conventional methods
Elad et al. (2008) ²⁵	Israel	Case report	Coronary angioplasty and subsequent drug-eluting stent because of ischemic heart disease and acute myocardial infarct <i>Relevant medication: aspirin 100 mg and clopidogrel 75 mg</i>	Nonsurgical periodontal treatment (scaling and root planing)	Severe gingival bleeding >10 h after postoperative hemostasis	—	4/0 vicril suture + local pressure with gauze soaked with tranexamic acid solution in the bleeding area
Federici et al. (2000) ³⁷	Italy	Cross-sectional	von Willebrand disease	Resective periodontal surgery + dental extractions (n = 63)	Severe gingival bleeding 6–8 h after postoperative hemostasis	3.1% (2/63)	Local application of fibrin glue in the bleeding area
Franchini et al. (2005) ³⁸	Italy	Cross-sectional	Severe hemophilia A	a. Nonsurgical periodontal treatment (scaling and root planing) (n = 133) b. Periodontal surgery (n = 19)	Severe gingival bleeding 48 h after postoperative hemostasis	a. 0.7% (1/133) b. 0.0% (0/19)	Factor VIII 2000 + 1500 IU after 12 h

TABLE 1 (Continued)

Authors (year)	Country	Study design	Systemic condition	Intervention	Complication	Complication rate	Complication management
Gregoriou et al. (1996) ³³	USA	Case series	Cerebral palsy with gingival overgrowth Relevant medication: phenobarbital	Gingivectomy (n = 2)	Severe gingival bleeding 2-3h after postoperative hemostasis	—	Transfusion of 250 cc of cross-matched O ⁺ blood and 1255 cc plasmanate (case 1) 6000 units of topical application of hemostatic agent thrombin powder (case 2)
Jones et al. (1988) ³⁴	USA	Case series	Cerebral palsy with gingival overgrowth Relevant medication: diphenylhydantoin	Gingivectomy (n = 24)	Slow to start adequate oral food intake	8.3% (2/24)	Not reported
Knapp and Fiori (1984) ²⁶	USA	Case report	Hypertension	Resective periodontal surgery	Prolonged gingival bleeding + hypertensive crisis	—	a. Gingival bleeding: not reported b. Hypertensive crisis: sodium nitroprusside drip
Lee et al. (2005) ⁴⁰	UK	Randomized controlled clinical trial (active 5% tranexamic acid mouthwash vs placebo)	Hemophilia A or B	Nonsurgical periodontal treatment (dental scaling) (n = 13)	Prolonged gingival bleeding	61.5% (8/13)	Not reported
Mattson et al. (1998) ²⁷	USA	Case report	Type 2 diabetes mellitus	Regenerative periodontal surgery (guided tissue regeneration using a collagen resorbable membrane)	Membrane exposure	—	Irrigation of surgical site with 0.12% chlorhexidine and diluted salt water
Mullally et al. (1993) ²⁸	UK	Case report	Type 1 diabetes mellitus	Regenerative periodontal surgery (guided tissue regeneration using a nonresorbable membrane)	Membrane exposure + candida infection	—	100000 units of Nystatin pastilles (4 times/d for 1 wk) + membrane removal + tooth extraction

(Continues)

TABLE 1 (Continued)

Authors (year)	Country	Study design	Systemic condition	Intervention	Complication	Complication rate	Complication management
Nishide et al. (2005) ²⁹	Japan	Case report	Chronic renal failure (under hemodialysis) with gingival overgrowth Relevant medication: <i>amlodipine</i>	Gingivectomy + periodontal surgery (modified Widman flap technique) + dental extractions	Extensive intraoperative gingival bleeding	—	Acrylic splints containing thrombin powder to cover surgical area + 4 units of concentrated red blood cells transfusion + regional anticoagulation hemodialysis with nafamostat-mesilate
Scheitler et al. (1988) ³⁰	USA	Case report	Plasminogen activator deficiency	Nonsurgical periodontal treatment (scaling and root planing) + dental extractions	Minimal intraoperative gingival bleeding	—	Direct pressure with gauzes
Shapiro (1993) ³¹	USA	Case report	Hemophilia C	Mucogingival surgery (free gingival graft)	Bleeding from the palatal donor site 5 d postsurgery	—	Ligation of lesser palatine artery with 4/0 silk suture and this was repeated on day 8 and 10 after surgery + 11 units of fresh frozen plasma
Thomason et al. (1997) ³²	UK	Case report	Renal transplant with gingival overgrowth Relevant medication: <i>cyclosporine</i> 450 mg/d, <i>azathioprine</i> 75 mg/d, <i>amlodipine</i> 10 mg/d, and <i>aspirin</i> 150 mg/d	Gingivectomy	Bleeding 40 min after postoperative hemostasis	—	Local hemostasis by means of pressure and infiltration of anesthetic with adrenaline + 6 units of platelets

Abbreviations: IU, International unit; Nd:YAG, neodymium-doped yttrium aluminum garnet.

TABLE 2 Examples of inherited and acquired bleeding disorders

Classification	Body system	Examples of medical conditions	
Congenital	Hematological	A Vascular disorders <ul style="list-style-type: none"> • Hereditary hemorrhagic telangiectasia 	
		B Platelet disorders <ul style="list-style-type: none"> • Bernard Soulier disease • Idiopathic thrombocytopenic purpura 	
		C Coagulopathies <ul style="list-style-type: none"> • Von Willebrand disease • Hemophilia 	
		D Fibrinolytic disorders <ul style="list-style-type: none"> • Plasminogen activator deficiency 	
Acquired	Cardiac	<ul style="list-style-type: none"> • Cyanotic congenital heart disease 	
	Connective tissue	<ul style="list-style-type: none"> • Ehlers Danlos Syndrome 	
	Liver disease	<ul style="list-style-type: none"> • Liver cirrhosis • Liver malignancy 	
Acquired	Renal	<ul style="list-style-type: none"> • Chronic kidney disease 	
	Hematological	<ul style="list-style-type: none"> • Aplastic anemia - pancytopenia 	
	Immune	<ul style="list-style-type: none"> • Systemic lupus erythematosus • Antiphospholipid syndrome • HIV • Immune thrombocytopenia purpura 	
		Malignancy	A Hematological malignancies <ul style="list-style-type: none"> • Leukemia • Lymphoma • Multiple myeloma • Myelodysplasia
			B Nonhematological malignancies: <ul style="list-style-type: none"> • Patients undergoing chemotherapy
	Drugs	<ul style="list-style-type: none"> • Alcohol • Antiplatelets • Anticoagulants • Nonsteroidal anti-inflammatory drugs • Corticosteroids • Chemotherapy 	
		Idiopathic	<ul style="list-style-type: none"> • Disseminated intravascular coagulation

A multicenter retrospective analysis of 247 patients with different bleeding disorders who received a total of 543 dental procedures presented an incidence of 1.9% of bleeding complications. Of those undergoing periodontal procedures ($n = 152$), only one participant diagnosed with severe hemophilia A experienced a hemorrhagic

episode, 2 days after subgingival instrumentation that was treated with factor VIII concentrate.³⁸ A pilot, randomized, double-blind, placebo-controlled clinical trial testing the use of active 5% tranexamic acid mouthwash before dental scaling in patients with hemophilia A/B reported that 38.5% of those who completed the study did not show any sign of gingival bleeding.⁴⁰ Bleeding complications from the palatal donor site when performing mucogingival surgery have been reported.^{22,31} Mitigating procedures reported to stop the bleeding include one from Shapiro,³¹ described as a ligation of lesser palatine artery with 4/0 silk suture, and this procedure was repeated two more times after surgery together with the use of 11 units of fresh frozen plasma. In the case reported by Blanco-Carrion et al,²² a combination of 2500 units of factor VIII concentrate twice a day during 1 week with prophylactic factor VIII concentrate (2500 units once every 2 days for two more weeks) was used to manage the same complication. Further, data from 63 consecutive patients with von Willebrand disease receiving dental extractions and surgical periodontal procedures were retrospectively analyzed. Results showed that the complication rate of severe gingival bleeding was 3.1% and this was managed through local application of fibrin glue in the bleeding area.³⁷ However, some case series did not find any bleeding episodes in patients with von Willebrand disease after either nonsurgical⁴² or surgical periodontal therapy.⁴³ Likewise, a low incidence of gingival bleeding in patients with HIV was reported in a cross-sectional study where different periodontal procedures were carried out.³⁵ When other inherited bleeding conditions such as plasminogen activator deficiency or hereditary hemorrhagic telangiectasia were evaluated, the risk of bleeding was minimal,³⁰ if any at all.⁴⁴

3.1.2 | Drug-induced gingival overgrowth

Gingival overgrowth may occur in patients taking anticonvulsants (eg, phenobarbital, sodium valproate, and phenytoin) (Figure 1), immunosuppressants (eg, ciclosporin), or calcium channel blocker antihypertensive drugs (eg, nifedipine and amlodipine).⁴⁵ Severe cases may require surgical excision of the enlarged gingiva. While a few case reports showed prolonged intraoperative and postoperative bleeding after gingivectomy,^{29,32,33} others did not find any bleeding episodes after gingival tissues were treated with both nonsurgical and surgical approaches.^{46,47} Jones et al³⁴ performed 39 gingivectomies in patients with cerebral palsy who presented gingival overgrowth resulting from diphenylhydantoin use and, although they did not observe any bleeding problems, two out of 12 patients had slow resumption of adequate oral food intake.

3.1.3 | Antithrombotics

Patients taking antithrombotic medications may present with extensive bleeding episodes after periodontal therapy. Most of these patients take anticoagulants (eg, warfarin, dabigatran, apixaban, and



FIGURE 1 Gingival overgrowth and bleeding tendency secondary to the administration of valproate in a patient with severe epilepsy.

rivaroxaban) or antiplatelet (eg, aspirin and clopidogrel) drugs, which makes them more prone to experience bleeding problems in the dental setting. A cross-sectional study of 45 patients who received cardiac valve surgery and were under oral anticoagulation therapy reported a low incidence (<5%) of bleeding independent of using a neodymium-doped yttrium aluminum garnet laser for periodontal surgery.³⁶ Uncontrolled severe gingival bleeding was also found after delivering scaling and root surface debridement on a patient who was taking aspirin and clopidogrel.²⁵

3.1.4 | Hypertension

Knapp and Fiori²⁶ described a case of prolonged postoperative bleeding and hypertensive crisis associated with resective periodontal surgery. In this case report, a patient diagnosed with hypertension (180/120 mm Hg) underwent periodontal treatment consisting of an initial phase on nonsurgical periodontal therapy followed by two apically repositioned flaps with osseous surgery. Two days after the second surgery, the patient began to bleed spontaneously from the surgical site and was unable to control the local hemorrhage. When the patient attended the emergency room, the amount of blood he had lost was approximately 100 mL/h and at that time the blood pressure was 210/140 mm Hg. He was given his normal dose of clonidine to stop the hypertensive crisis, but no apparent effect was noted. Immediately, a sodium nitroprusside drip was started in the intensive care unit, where his blood pressure dropped to 130/88 mm Hg. Once the blood pressure was stabilized, oral bleeding stopped and healing of the periodontal surgical site was uneventful.

3.2 | Other complications

Soft tissue complications after mucogingival surgery have been described in two case reports.^{21,22} The first case consisted of a patient

diagnosed with Crohn's disease (a type of inflammatory bowel disease) who presented with multiple Miller's class I gingival recessions. Three different mucogingival surgeries with a 4-week interval difference were carried out using a coronally advanced flap technique and an enamel matrix derivative was used before coronally repositioning the flap in the last two procedures. Two of the three surgeries (one with and another without the use of amelogens) showed incomplete healing, with a red and swollen appearance of the surgical area that lasted up to 6 weeks. To manage these complications, chlorhexidine gluconate gel and mouthwash were administered. Another study reported a case of a patient with hemophilia and HIV requiring a root coverage procedure of single Miller's class II gingival recession that was carried out by applying a subepithelial connective tissue graft technique. At 1 week postsurgery, the palate (donor site) showed secondary intention healing associated with the necrotic area.²² Conversely, another case report describes a patient with HIV who received the lateral sliding flap technique and experienced uneventful healing over 8 months.⁴⁸ In a case series of 21 patients with HIV, the same authors found no complications (ie, delayed healing or infection) after crown lengthening had been undertaken.⁴⁹

Delayed healing could be expected after periodontal procedures in patients experiencing dystrophic epidermolysis bullosa, as described in two case reports. These cases detail one patient who underwent mucogingival procedures to cover exposed roots by means of a coronally positioned flap combined with a subepithelial connective tissue graft,⁵⁰ and another who received an acellular dermal matrix allograft to increase the width of the attached gingiva.⁵¹ Neither patient developed any complications either during or after surgery.

Diabetes mellitus is also known to be associated with impaired wound healing, and patients are more likely to develop infections. Mattson et al²⁷ treated an intrabony defect with guided tissue regeneration from a patient with type II diabetes mellitus.²⁵ Resorbable collagen membrane exposure was noticed after 1 week of healing.²⁷ The membrane was not removed but was irrigated with chlorhexidine and diluted salt water until the soft tissue had healed.²⁷ Similarly, Mullally et al²⁸ also reported membrane exposure after a guided tissue regeneration procedure in a patient with diabetes mellitus. Moreover, a fungal infection by *Candida albicans* was diagnosed clinically and confirmed histologically afterwards.²⁸ In this case, the membrane was removed, the tooth extracted, and antifungal medication was prescribed.²⁸ Conversely, in a patient with type I diabetes mellitus, the formation of "liver clots" (without clot retraction for up to 10 days) resulting from poor healing 1 week after modified Widman surgery and the extraction of hopeless teeth was observed.²³ However, this finding is not common and results from a recent randomized controlled clinical trial including patients with type II diabetes mellitus and moderate-to-severe periodontitis showed a low incidence of complications after periodontal treatment. D'Aiuto et al³⁹ did not find any statistically significant differences in terms of oral and systemic complications when intensive periodontal therapy (including subgingival

debridement and modified Widman flap surgery) was compared with a control treatment (only supragingival scaling) over a period of follow-up lasting 1 year.

There are some medications such as antiresorptives and antiangiogenics that could also interfere in both soft and hard tissue healing. A case has been published reporting osteonecrosis of the jaw after nonsurgical periodontal therapy on a patient who was receiving subcutaneous injections of denosumab every 6 months (Figure 2).²⁴ The complication was managed by means of administration of chlorhexidine mouthwash and systemic antibiotics (doxycycline) together with removal of the affected teeth, sequestrectomy, and surgical debridement of necrotic bone.

4 | RISK ASSESSMENT FRAMEWORK AND APPROPRIATE TREATMENT MODIFICATIONS

When planning treatment for periodontal therapy in patients who are medically compromised, it is important to consider additional factors to provide holistic care. In addition to clinical and radiographic examination, a thorough medical, social, and dental history will enable a comprehensive risk assessment (Table 3). This will ensure that appropriate modifications can be implemented prior to commencement of periodontal therapy, thereby reducing complications and treatment errors. The ACCESS mnemonic^{52,53} is a systematic approach to treatment modification, considering six domains that address different aspects of care:

1. Access
2. Communication
3. Consent
4. Education
5. Surgery
6. Spread of infection



FIGURE 2 Medication-related osteonecrosis of the jaw after nonsurgical periodontal therapy on a patient under antiangiogenics (denosumab).

These domains will be explored further throughout this review with specific examples (Table 4).

5 | PREVENTION AND MANAGEMENT OF COMPLICATIONS AND TREATMENT ERRORS IN PERIODONTAL THERAPY

Complications and treatment errors may occur when providing periodontal therapy in patients who are medically compromised. These will be presented in relation to pain control, bleeding, infection, and wound healing.

5.1 | Analgesia and pain control

Effective pain control is essential for delivery of invasive periodontal procedures. Adaptations may be required in relation to certain medical conditions, operator skills, and availability of equipment, for instance, a computer-controlled local anesthetic delivery system.

The type, dose, and technique for local anesthetic administration may need consideration. For example, patients may have resistance to local anesthetic, as in the case for the hypermobile type of Ehlers Danlos Syndrome. These patients require a systematic approach to the type of local anesthetic selected.⁵⁴ It may be administered in order of potency⁵⁵ or in combination, for instance lidocaine could be administered first, followed by articaine and then bupivacaine. A retrospective survey of 980 people with Ehlers Danlos Syndrome reported the highest success rate of 30% with articaine, followed by bupivacaine at 25%.⁵⁶ When it is not possible to achieve adequate local anesthesia, alternative anesthetic modalities should be considered.

Allergy to local anesthetic and its constituents is rare, and is estimated to have an incidence of less than 1%.^{57,58} Further information should be sought to determine the nature of the reported allergy, and, where appropriate, the patient should be referred for formal allergy testing.⁵⁹ The most commonly reported reaction to local anesthetics is vasovagal syncope, which the patient may report as an allergy.⁶⁰

The dose of local anesthetic solution may need to be administered with caution in patients with a severe cardiac condition. Good pain control is essential to minimize stress on the myocardium secondary to pain sensation. The local anesthetic should be administered slowly with an aspirating syringe to assess the physiological response and reduce the risk of cardiovascular toxicity.⁵⁸ There is insufficient evidence to suggest that local anesthetic with or without adrenaline as a vasoconstrictor poses a risk to patients with hypertension or other cardiomyopathies.⁶¹ However, anesthetics with adrenaline should be avoided in patients with severe hypertension and it is not recommended to use more than two anesthetic cartridges with adrenaline at 1:100000 (0.04 mg) in patients with certain cardiac conditions, such as those with coronary stents or those with a history of myocardial infarction.⁵⁸

TABLE 3 Examples of potential medical, social, and dental risks

Category	Potential risks
Medical	Aspiration Bleeding Delayed healing Local infection Infective endocarditis Hypoglycemia Trismus
Social	Ability to attend appointments Timing of appointments Communication aids Lack of capacity to consent to periodontal therapy Reduced mobility
Dental	Periodontal disease Reduced cooperation Reduced manual dexterity

Patients with long-term use of opioids, for instance, because of chronic pain syndrome, may present with increased tolerance to local anesthetic. Studies on nondental procedures showed that a higher dose of local anesthetic solution was required to achieve the same efficacy.⁶² An increased amount of local anesthetic solution may be required for dental procedures.

Modification of the technique used to deliver local anesthetic may be required in relation to the underlying medical condition. For example, patients with severe bleeding disorders require careful assessment if inferior alveolar nerve blocks or lingual infiltrations are planned, as hematological support (eg, coagulation factor replacement) will be needed.⁶³ The risks of proceeding without this in place are significant and include hematoma formation and potential risk to the airway. Buccal infiltration has been reported as a safe technique in patients with differing severity of hemophilia, without the need for additional factor cover.⁶⁴ Preoperative tests may be required for patients on anticoagulants such as warfarin for whom inferior alveolar nerve blocks are required. The clinician should confirm that the patient's international normalized ratio readings are generally stable. For patients with unstable international normalized ratio profiles, it has been proposed that the international normalized ratio should be checked preoperatively if block injections are planned and given cautiously with a self-aspirating syringe.^{65,66}

In patients with trismus, alternative techniques to the conventional inferior alveolar nerve block may be indicated. Gow-Gates and Akinosi techniques deliver the local anesthetic solution higher than the conventional technique and have similar anesthetic efficacy.⁶⁷⁻⁶⁹ These may be considered in patients with trismus or when the conventional technique fails. Both alternative techniques should be used with caution, and each carries a higher risk of complications.⁶⁷ Intraligamentary and intraosseous anesthetic injection techniques may be used as alternatives to mandibular nerve blocks.⁷⁰

Computer-controlled local anesthetic delivery systems can be utilized in patients with needle phobia, especially if there are additional medical comorbidities that contraindicate alternative anesthetic modalities.^{71,72} The technique can be used in children and adults, and has been found to reduce the perceived pain on

administration, and to achieve greater efficacy compared with the conventional local anesthetic technique.^{71,73} It has been suggested that a computer-controlled intraosseous anesthesia system may be useful for root planing procedures because it reduces the pain of the injection and provides a larger area of anesthesia with a single puncture.⁷⁴ In a randomized split-mouth study in patients with chronic periodontitis who underwent open-flap debridement on premolars and molars, the authors reported substantial relief from injection pain with a computer-controlled anesthetic delivery system compared with a conventional local anesthetic technique.⁷⁵

An aspirating local anesthetic syringe should always be used.⁵⁸ The local anesthetic solution should be delivered in areas without localized inflammation and/or infection, as the presence of inflammation may affect the success of local anesthesia. Block techniques are useful adjuncts in these instances, as the local anesthetic solution is deposited at a site away from inflammation and infection.⁷⁶

In patients with fragile mucosa surfaces, as in the case of epidermolysis bullosa, the technique may need to be altered. Depending on the severity, the local anesthetic solution should be deposited slowly and deeply in the tissues to avoid mechanical separation of the mucosal layer and the formation of blisters.⁷⁷ If iatrogenic blisters appear as a result of the injection of local anesthesia, they must be drained to prevent the lesion from expanding (puncturing with a needle or cutting the blister with scissors).⁷⁸ Postoperatively, patients should also be instructed to take extra care to avoid traumatizing the mucosa.⁷⁷

If adequate local anesthesia is not achievable, alternative anesthetic modalities may need to be considered, such as conscious sedation and general anesthesia. In patients who are medically compromised, preoperative anesthetic assessment may be required to assess their suitability.⁵² Postoperative pain is common among patients undergoing periodontal treatment, and it has been suggested that it is conditioned by variables such as age, the degree of patient anxiety, and the type of procedure performed.⁷⁹ Scaling and root planing can cause considerable pain in terms of intensity and duration,⁸⁰ although the magnitude of pain is generally greater after surgical periodontal treatment.¹⁶ Acetaminophen (paracetamol) and

TABLE 4 The ACCESS risk assessment and treatment modification framework

Domain	Considerations	Examples of conditions that may require adaptations	Examples of treatment modification		
Access	Appropriate dental setting	Bleeding	Low platelets (eg, secondary to chemotherapy, platelet disorders)	Patients requiring platelet support should ideally be seen in a hospital setting	
		Access to the dental surgery	Timing of appointment	Antithrombotic medications (eg, oral anticoagulants, antiplatelets)	Appointments early in the day and week for invasive dental procedures
	Escort		Chronic kidney disease and dialysis	Appointment the day after dialysis	
			History of myocardial infarction	Avoid elective dental procedures within 6 mo of myocardial infarction	
	Access to the patient's mouth	Transport	Learning disability, dementia	Depending on severity, may require family member and/or carer to accompany the patient	
			Wheelchair access	Frailty, physical disability	Hospital transport
		Aspiration	Wheelchair user	Wheelchair recliner if unable to transfer to the dental chair	
			Dysphagia	Semisupine or upright position in the dental chair	
			Involuntary movement	Movement disorders (eg, Parkinson's disease)	Vacuum cushion and/or clinical holding to support the head and neck to minimize trauma
			Temporomandibular dysfunction	Ehlers Danlos Syndrome	Mouth prop, frequent breaks, and shorter appointments
Trismus	Head and neck cancer therapy	Pediatric handpieces, mouth prop			
Fragile oral mucosa	Epidermolysis bullosa	Lubrication and careful handling of soft tissues			
Communication	With the medical team	Obesity, previous surgery to the head and neck	Alternative technique to deliver local anesthetic may be required		
		Immunosuppression (eg, transplant)	The ideal timing for elective periodontal therapy should be consulted with the medical team		
	With the laboratory	Low neutrophils (eg, secondary to chemotherapy)	Timely reporting of urgent blood tests prior to invasive periodontal therapy		
	With social care professionals	Learning disability, mental health conditions	Assistance in organizing appointments for patients who require additional social support		
	With patients	Nonverbal communication (eg, stroke, learning disability)	Communication aids (eg, Makaton, pictures, and easy read patient information leaflets)		
Consent	Capacity to consent	Learning disability, mental health conditions, dementia	Undertake capacity assessment, if lacks capacity to consent to specific periodontal therapy, involve family and/or carers in the decision-making process		
	Fatigue	Fatigue related to the medical condition	Undertake capacity assessment, avoid early morning appointments		
	Implications in relation to medical health	Infection risk in patients who are immunocompromised (eg, cancer)	Extraction of teeth with infection risk because of the potential impact on their systemic condition		
	Long-term implications	Neurodegenerative conditions (eg, dementia, Parkinson's disease)	Discuss the patient's ability to maintain oral hygiene as the condition progresses		

(Continues)

TABLE 4 (Continued)

Domain	Considerations	Examples of conditions that may require adaptations	Examples of treatment modification	
Education	Relationship between medical conditions and dental disease	Diabetes mellitus	Patient informed of the bidirectional relationship between periodontal disease and diabetes mellitus, and the importance of managing good periodontal health	
	Education of family and/or carers	Learning disability, neurodegenerative conditions (eg, dementia, Parkinson's disease)	Oral hygiene instructions to the family and/or carers for patients who are partly or fully dependent on others for activities of daily living	
	Reduced manual dexterity	Cerebral palsy, multiple sclerosis	Adaptation of oral hygiene tools (eg, toothbrush handle holder, and long-handled interdental brushes)	
	Dental team	Unstable asthma, angina, epilepsy	Medical emergency training	
Surgery	Preoperative	Blood test	Low neutrophils (eg, chemotherapy)	Full blood count may be required within 24 h prior to invasive periodontal therapy
		Blood test	Warfarin	INR test within 24 h (or 72 h if stable) prior to invasive periodontal therapy
		Antibiotics	Special consideration group for infective endocarditis (eg, prosthetic heart valve, previous infective endocarditis)	Antibiotic cover 1 h before invasive periodontal therapy may be required after consulting the patient and their cardiologist
	Perioperative	Local anesthesia	Resistance to local anesthesia (eg, Ehlers Danlos Syndrome)	Select the most appropriate local anesthetic agent
		Monitoring vital signs	Moderate to severe respiratory condition	Monitoring of vital signs
		Oxygen	At risk of hypoxia (eg, sickle cell disease)	Supplemental oxygen via nasal cannula during invasive periodontal therapy
	Postoperative	Prescription	Patients on warfarin	Avoid prescribing metronidazole because of drug interactions
		Follow-up	At risk of osteoradionecrosis (eg, head and neck cancer)	Review 8 wk after invasive periodontal therapy
	Emergency access	Bleeding disorders	Details of emergency services for patients at higher risk of bleeding	
Spread of infection	Patients who are immunocompromised	Patients undergoing chemotherapy	May require prophylactic antibiotics; consult the medical team	

Abbreviation: INR, international normalized ratio.

nonsteroidal anti-inflammatory drugs are the agents of choice to tackle postoperative pain in dentistry,⁸¹ but they are not exempt from adverse effects and should be administered with caution in patients with certain systemic diseases.⁸² The interval between acetaminophen intakes should be adjusted in patients with chronic kidney disease and the total daily dose should be limited in patients with liver disease.⁸³ Most nonselective cyclooxygenase-1 and cyclooxygenase-2 inhibitor nonsteroidal anti-inflammatory drugs should be avoided in patients with a history of peptic ulcer or gastroesophageal bleeding, in patients receiving anticoagulants, lithium, or methotrexate, with uncontrolled hypertension and

chronic kidney disease, or with severe liver failure.⁸⁴ Nonsteroidal anti-inflammatory drugs that act as preferential cyclooxygenase-2 inhibitors have also been used to control postoperative pain after periodontal procedures.^{85,86} Cyclooxygenase-2 inhibitors reduce the incidence of gastrointestinal side effects and have little or no effect on platelet function, so the risk of bleeding is minimal. However, most selective cyclooxygenase-2 inhibitors have been withdrawn from the market because of the risk of serious cardiovascular events,⁸⁷ and nimesulide is also not marketed in some countries because of the risk of acute hepatotoxicity and should not be administered to patients with liver failure.⁸⁸

5.2 | Bleeding

There are congenital and acquired bleeding conditions that may increase the risk of bleeding perioperatively and postoperatively (Table 2). Treatment modifications will be explored to reduce the risk of bleeding resulting from periodontal therapy.

The dental setting should be selected based on the risk of bleeding in relation to the medical condition, dental procedure, and experience of the operator.⁸⁹ The clinician should establish whether the patient is under the care of a medical team and consult with them to confirm the severity of their condition and management plan. This will aid in determining the level of risk of bleeding as a complication and/or treatment error in periodontal therapy. For instance, patients who are undergoing chemotherapy for the management of malignant conditions can receive different types of agents. Some agents will predispose the individuals to chemotherapy-induced thrombocytopenia, and others will impact platelets to a lesser degree.⁹⁰ Patients with severe risk of bleeding who require onsite medical support for invasive periodontal therapy are more appropriately managed in a secondary care setting.⁹¹

If the planned periodontal therapy has an increased risk of bleeding, the appointment should be timed earlier in the day and the week, so that postoperative complications can be managed accordingly.⁶⁶ The timing of appointments should be in line with the medical management of each patient's condition. For instance, patients who are taking direct oral anticoagulants should provide information about the time of the scheduled dose so as to minimize interruption to the drug regime.⁶⁶ The risk of thrombosis outweighs the potential risks of postoperative bleeding from dental procedures.⁶⁶ Similarly, single or dual therapy antiplatelets should not be interrupted for dental procedures,⁹² including periodontal therapy.⁶⁶ However, in patients with a high risk of bleeding and dual therapy, some guidelines have recommended suspending one of the antiplatelet agents before the procedure (5 days in the case of clopidogrel), generally maintaining the administration of aspirin.⁹³ For patients with hemophilia who have regular prophylactic factor replacement, the dental procedure should be timed as close to the time of administration to avoid the need for additional factor replacement, and thus maximizing therapeutic effects, and reducing risks and overall treatment costs.^{63,89,94,95} Patients undergoing renal dialysis should not be seen on the dialysis day because of fatigue and an increased risk of bleeding secondary to heparin and abnormal platelet function.⁹⁶

Depending on the underlying cause of the increased bleeding risk, special investigations may be indicated. Appropriate blood tests such as full blood counts, clotting screen, and liver function tests should be arranged as part of the preoperative assessment depending on the medical condition and its stability⁹¹ (Figure 3). The timing of the blood test needs to reflect the underlying medical condition and its treatment regime. For example, it is acceptable to use a 72-hour international normalized ratio test on patients on warfarin who are stable, but for those with an unstable international normalized ratio, it should be undertaken within 24 hours.^{65,66} Point-of-care tests for international normalized ratio are available and can be used



FIGURE 3 Multiple hematomas following scaling and root planing in a patient with liver cirrhosis.

in the dental setting. The international normalized ratio should be <4 to undertake periodontal therapy.^{65,66} Morimoto et al⁹⁷ undertook a retrospective study on periodontal therapy in patients taking warfarin. They confirmed that nonsurgical periodontal therapy can be safely performed when the international normalized ratio is <4 , and that surgical periodontal therapy surgery can be safely performed when the international normalized ratio is <3 . These international normalized ratio values are applicable in patients without other concomitant factors that may favor bleeding, such as liver failure or uncontrolled hypertension.⁵⁸

Furthermore, for patients having pharmacotherapy that affects their blood counts, they may require a blood test on the day of the procedure or within the last 24–48 hours to account for more frequent fluctuations in blood counts.⁹⁸ It may also be necessary to liaise with the laboratories regarding specific requirements and timely reporting of the investigation results.

Additional hematological support may be required in patients with thrombocytopenia. This will be dependent on the planned periodontal procedure, as well as a preoperative blood test and liaison with the medical team to determine the requirements for platelet transfusions. The most accepted threshold for platelet counts is $\geq 50 \times 10^9/L$ for invasive dental procedures, which includes periodontal surgery or tooth extractions. Patients with platelet counts of $< 50 \times 10^9/L$ are at an increased risk of experiencing perioperative and postoperative bleeding.⁹⁹ Platelet transfusion may be indicated preoperatively, perioperatively, and/or postoperatively. Karasneh et al¹⁰⁰ systematically reviewed the evidence on a platelet count threshold of $< 50 \times 10^9/L$ for platelet transfusions for invasive dental procedures. Two out of nine studies included patients with thrombocytopenia who underwent scaling. One of these studies had a lower threshold of $\leq 30 \times 10^9/L$ for prophylactic platelet transfusion for three patients who required scaling. Overall, there was insufficient evidence to suggest that a platelet count of $\geq 50 \times 10^9/L$ or prophylactic platelet transfusions prevented significant postoperative bleeding. Local measures were sufficient in managing bleeding. The studies included in the review were small cohort studies that were heterogenous. Another retrospective cohort study

investigated bleeding complications in patients with mild to severe thrombocytopenia after extractions.¹⁰¹ Over half of the patients displayed evidence of chronic periodontitis, although the reasons for the extractions were not specified. Only four out of 89 (4.4%) patients experienced postoperative bleeding. Prophylactic platelet transfusions did not reduce the risk of bleeding. Inherited qualitative platelet disorders are a broad spectrum of diseases characterized by platelet dysfunction in the early phases of hemostasis (eg, Bernard-Soulier syndrome or Glanzmann's thrombasthenia). Traditionally, the treatment of these patients has been carried out under platelet transfusion.¹⁰² However, based on the high rate of alloimmunization to platelet surface antigens and human leukocyte antigens, recent guidelines recommend the use of tranexamic acid and desmopressin, avoiding prophylactic platelet transfusions, and restricting their therapeutic administration only for severe inherited functional platelet disorders and unresponsive cases.¹⁰³

In relation to patient education and the risk of bleeding, patients should be informed of possible minor bleeding related to the planned periodontal therapy. There is a tendency for patients with bleeding conditions to use soft toothbrushes, which may not effectively remove plaque deposits. In addition, patients may have been advised by their doctors to avoid brushing their teeth or to undertake interdental cleaning measures when they have thrombocytopenia. There is a lack of evidence to suggest the benefits of such an approach.¹⁰⁴ A study conducted by Padrón et al¹⁰⁵ concluded that patients under anticoagulation therapy had greater accumulations of dental plaque, more gingival bleeding, and deeper periodontal pockets than healthy controls, and approximately 17% of them never brushed their teeth compared with 3% of the control group. It has been suggested that fear of gingival bleeding could induce patients using anticoagulants to brush their teeth less.¹⁰⁵ A lack of good oral hygiene measures may predispose the patient to dental disease, and possibly progress to infection, which may compromise their medical health. Dental professionals should consider the risk of bleeding before advising on the most appropriate oral hygiene measure.

For all types of procedures, general precautions should be followed, including gentle handling of the oral mucosa, instruments, and equipment.¹⁰⁶ For pain and anxiety control, appropriate selection of local anesthetic solution and technique is required. Factor replacement may be required for patients with hemophilia in relation to the local anesthetic technique and proposed procedure.⁹¹ The site of surgery helps to determine an appropriate local anesthetic technique for treatment. In patients with hemophilia and other severe bleeding conditions, inferior alveolar nerve blocks and lingual infiltrations pose a risk of airway obstruction, caused by hemorrhage into musculature and the formation of hematomas in retromolar and pterygoid spaces.¹⁰⁷ Factor replacement decreases the risk of bleeding.⁹⁴ On the contrary, infiltrations (with the exception of lingual), as well as intraligamentary, intraosseous, and intrapulpal injections, do not require factor replacement.¹⁰⁸ Articaine infiltrations may be used in the mandible to avoid block techniques^{109,110} and eliminate the need for factor cover.¹¹¹

Low-risk procedures for bleeding include nonsurgical periodontal therapy.¹¹² No additional hematological cover is necessary, provided local anesthesia principles are followed.¹¹³ Although routine scaling is unlikely to cause significant bleeding, the overall periodontal condition must be assessed, as hematological support may be indicated in selected cases.⁸⁹ High-risk procedures consist of extractions and periodontal surgery.¹¹² The degree of prophylaxis cover is determined by the hematologist. Local hemostatic measures should be followed, including closure of surgical sites and the use of hemostatic agents.¹¹⁴ The use of a surgical splint has been suggested to protect the surgical site.⁹⁴

Initially, the treatment area should be limited and staged to assess the bleeding risk, and reassessed before proceeding.⁶⁶ Surgical trauma should be minimized where possible, with closure of the wound. At the end of the procedure, the procedural site should be observed for an extended period of time to ensure that there is hemostasis. If there is evidence of bleeding, the site should be compressed with a damp gauze dressing for 10-15 minutes. Consider the use of topical coagulating agents such as oxidized cellulose and gelatin foam to aid hemostasis.^{66,115} Rubino et al¹¹⁵ undertook a retrospective analysis of patients who had invasive periodontal therapy and were on antithrombotic medications (antiplatelets and anticoagulants). The drug regime was not interrupted for most participants (99.6%), and local hemostatic measures were followed. Postoperative bleeding was only observed in three out of 867 procedures (0.35%).

A prescription for tranexamic acid 5% mouthwash, an antifibrinolytic agent, may be considered for use up to four times a day as required. This is a nonformulary preparation and therefore may not be readily accessible in primary care dental services. Successful use of a 2-day course of tranexamic acid 4.8% mouthwash in the management of postoperative bleeding was reported for patients taking warfarin who received tooth extractions because of severe periodontal disease and the results were similar to those obtained for a 5-day course.¹¹⁶ To manage the bleeding, participants were initially asked to use compression with a gauze pad for 20 minutes, and if the bleeding persisted, the tranexamic acid mouthwash was applied via a gauze pad for a further 20 minutes. Systematic reviews of the evidence on the use of topical tranexamic acid for dental procedures showed successful hemostasis for patients on vitamin K antagonists,¹¹⁷ and inconclusive evidence for congenital bleeding disorders.¹¹⁸ If local measures are insufficient to achieve adequate local hemostasis, the appropriate medical team should be contacted to assess the need for systemic agents.

Postoperatively, the dental practitioner should ensure that patients have access to dental emergency services to minimize distress for the patient and facilitate timely access if required.⁶⁶ Prescription should be administered with caution. Nonselective cyclooxygenase-1 and cyclooxygenase-2 inhibitor nonsteroidal anti-inflammatory drugs for pain control should be avoided in patients at risk of bleeding, as this may exacerbate the risk of bleeding.^{66,119} Acetaminophen is the preferred analgesic.

5.3 | Infection

Infection may occur following periodontal therapy in patients who are medically compromised. This will be discussed in relation to immunosuppression, infective endocarditis, aspiration pneumonia, blood-borne viruses, and wound healing.

5.3.1 | Immunosuppression

Patients who have immunosuppression are at an increased risk of infection after invasive periodontal therapy. The causes of immunosuppression can be categorized into congenital and acquired (Table 5).

The timing of the dental appointment should be made taking into consideration the cause, severity, and the likely duration of the immunosuppression. For example, nonurgent periodontal therapy should be postponed for patients undergoing active chemotherapy.^{98,120,121} Patients may have bone marrow suppression, and resultant low white cell count and neutrophils, which predisposes them to

TABLE 5 Examples of congenital and acquired immunosuppressive disorders

Classification	Body system	Example of conditions
Congenital	Syndromes	<ul style="list-style-type: none"> Down syndrome Kostmann syndrome Chediak Higashi syndrome
	Metabolic	<ul style="list-style-type: none"> Glucose-6 phosphate dehydrogenase deficiency
Acquired	Endocrine	<ul style="list-style-type: none"> Diabetes mellitus Addison's disease
	Liver disease	<ul style="list-style-type: none"> Liver cirrhosis
	Renal	<ul style="list-style-type: none"> Chronic kidney disease
	Hematological	<ul style="list-style-type: none"> Aplastic anemia Thalassemia Sickle cell disease
	Immune	<ul style="list-style-type: none"> HIV Rheumatoid arthritis Systemic lupus erythematosus
	Malignancy	<ul style="list-style-type: none"> Hematological (secondary to the malignancy and treatment; eg, chemotherapy, radiotherapy, transplant) Nonhematological (secondary to treatment; eg, chemotherapy, radiotherapy, transplant)
	Drugs	<ul style="list-style-type: none"> Corticosteroids Immunosuppressants (calcineurin inhibitors, antimetabolite agents, polyclonal and monoclonal antibodies, mTOR inhibitors)

infections. Acute periodontal infection should be treated in a timely manner as it poses a risk of bacteremia and sepsis in patients with neutropenia.¹²² The ideal treatment window period should be determined after consultation with the oncology team,⁹⁸ for instance between chemotherapy cycles.

Another group of patients for which the timing of dental treatment is important consists of those who have had solid organ transplantation. This cohort receive long-term immunosuppressants, with a lower maintenance dose after approximately 6 months. Therefore, elective periodontal therapy should be delayed for 3-6 months after the transplant.^{123,124} Georgakopoulou et al¹²³ reported an increased level of risk of severe oral infections in patients who have undergone renal transplantation. The recommendation for routine periodontal therapy 6 months posttransplant is that scaling can be undertaken in a staged manner, with a small number of teeth cleaned at a time. Invasive periodontal therapy may require further preoperative investigations and close liaison with the patient's physician. To minimize the risk of infection when patients are immunosuppressed, a pretransplant dental assessment should be undertaken.^{124,125} Periodontal health should be stabilized, and the source of infection eliminated.¹²⁴

For patients who require regular blood transfusions (eg, thalassemia major) or red cell exchange transfusions (eg, sickle cell anemia), the dental visit should be scheduled soon after their routine transfusions.^{126,127} Treatment on the same day should be avoided as the patients are fatigued.¹²⁷ In addition, patients with hemoglobinopathies (eg, thalassemia, sickle cell disease) may have either nonfunctional or absence of spleen. This predisposes individuals to infections, and potential sources of periodontal infection should be managed in a timely manner.^{127,128}

Preoperative investigations may be required to determine the severity of immunosuppression including complete blood count with differential, coagulation assessment and liver and kidney function tests, to evaluate whether the procedure should be delayed, if it can be done in an outpatient setting, the need for antibiotic prophylaxis, the risk of bleeding, and the dosage of prescriptions. For example, for patients at risk of neutropenia, a preoperative full blood count should be undertaken prior to invasive periodontal procedures. If the neutrophil count is $<1 \times 10^9/L$, periodontal probing and elective invasive periodontal therapy should be postponed because of an increased risk of infection.¹⁰⁴ In an observational study, 10 out of 116 patients (8.6%) with mild ($1.00-1.50 \times 10^9/L$), moderate ($0.50-0.99 \times 10^9/L$), and severe ($<0.0-0.49 \times 10^9/L$) neutropenia who had extractions presented with one or more complications.¹²⁹ The most common complication was delayed healing,⁷ followed by postoperative pain⁶ and surgical site infection.³ The likelihood of complications was not associated with the severity of neutropenia. The preoperative management was variable, with some participants receiving preoperative, perioperative, and/or postoperative antibiotics and granulocyte colony-stimulating factor to increase neutrophil levels.

Prophylactic administration of antibiotics may be indicated in patients who are immunosuppressed.¹³⁰ For example, in patients who have had a splenectomy (eg, thalassemia and sickle cell disease), antibiotic cover should be considered for invasive dental

procedures.^{127,131,132} Those who are on immunosuppressive therapy constitute another cohort of patients. The American Association of Pediatric Dentistry advises that antibiotic coverage may be required for patients with a neutrophil count of $<2 \times 10^9/L$, and should be discussed with the medical team.¹³³ The suggested antibiotic regime is that used for infective endocarditis,¹³⁴ although in some cases it is necessary to consult with the medical team (eg, patients with severe immunosuppression, solid organ transplant recipients, or those who have received multiple antibiotic regimens).

The risk of developing systemic infection from a dental source has been reported to be associated with the presence of preexisting infection.¹³⁰ A timely and more aggressive antibiotic regime may reduce the risk of infection and its impact on the general health of patients who are immunosuppressed.^{130,133}

On the contrary, the British Society for Antimicrobial Chemotherapy do not recommend routine use of prophylactic antibiotics for dental procedures in patients who are immunosuppressed.¹³⁵ This is supported by the antimicrobial dental guidelines for immunocompromised patients, including diabetes mellitus, HIV, chemotherapy, solid organ transplants, and hematological malignancies.¹³⁶ The case-specific decision is advised by consulting with the medical team, as there may be additional medical factors that indicate the use of antibiotics (Figure 4).

Corticosteroids can cause immunosuppression, predisposing an individual to infections. Patients on a higher dosage of corticosteroids and who have Addison's disease are at an increased risk of adrenal crisis when exposed to stress. A literature review found that adrenal crisis related to dental procedures is rare.¹³⁷ The risk is increased in the presence of pain and infection, in addition to invasive procedures, and treatment under general anesthesia. Steroid cover is indicated for patients taking ≥ 7.5 to 10 mg prednisolone for longer than 3 months and undergoing invasive periodontal therapy and/or treatment under general anesthesia.^{138,139} If the patient is on other corticosteroids, the equivalent dose to prednisolone should be calculated, and advice



FIGURE 4 Patient with severe primary immunodeficiency who has received several antibiotic regimens. Before carrying out periodontal treatment, the medical team was consulted, who recommended microbiologic and antimicrobial susceptibility testing.

followed accordingly. Patients taking above 50 mg prednisolone are close to the innate maximum cortisol level seen in patients when stressed and may not require further supplementation.¹³⁹

In recent years there have been great advances in targeted anti-cancer therapies, including monoclonal antibodies, fusion proteins, tyrosine kinase inhibitors, and mammalian target of rapamycin inhibitors, among others.¹⁴⁰ The indications for biologic response modifiers, and in particular monoclonal antibodies, have been extended to numerous cardiovascular and inflammatory diseases (eg, rheumatoid arthritis, psoriasis, or Crohn's disease), transplant rejection, multiple sclerosis, and viral infections.⁸² In addition to the immunosuppressive effect, these molecules can cause thrombocytopenia, wound delayed healing, and medication-related osteonecrosis of the jaw.¹⁴⁰

5.3.2 | Infective endocarditis

Patients with susceptible cardiac conditions are at an increased risk of infective endocarditis following invasive dental procedures. Oral pathogens have been implicated in infective endocarditis, namely, viridans streptococci.¹⁴¹⁻¹⁴³ Periodontal bacterial species such as *Aggregatibacter actinomycetemcomitans* have been detected in specimens from damaged heart valves and aortic aneurysm walls.¹⁴⁴ Dhotre et al¹⁴² reported, in a series of confirmed cases of infective endocarditis undergoing dental extractions, that more than 40% had periodontitis, suggesting that periodontal disease enhances *viridans streptococcal* bacteremia. The prevalence of bacteremia resulting from periodontal pathogens is probably underestimated because of the limitations of microbiologic detection techniques.¹⁴⁵

Bacteremia may result from noninvasive dental procedures. Toothbrushing has been reported as a potential risk factor for infective endocarditis.^{146,147} A randomized controlled trial reported a lower incidence of infective endocarditis with toothbrushing compared with extractions.¹⁴⁸ However, as toothbrushing is performed more frequently on a daily basis, over time it may potentially have a comparable or higher cumulative risk. Patients should be informed of the importance of maintaining good oral hygiene,¹⁴⁹ which will subsequently reduce the incidence of bacteremia as well as the need for invasive dental procedures.¹⁴³

Invasive periodontal treatment can cause bacteremia leading to the development of endocarditis, although the relationship between dental treatment and infective endocarditis remains a controversial issue.¹⁵⁰ Transient bacteremia following dental procedures depends on the state of oral health and the treatment modality, estimating after scaling and root planing in 25%-61%.¹⁵¹ The rationale for antibiotic prophylaxis prior to invasive procedures is to reduce the bacteremia and subsequently the presumed reduced risk of infective endocarditis. For patients requiring invasive dental procedures, antibiotic prophylaxis is not routinely recommended by the National Institute for Health and Care Excellence (UK) guidelines.¹⁴¹ There are patient cohorts that are more susceptible to infective endocarditis, requiring special consideration.¹⁴⁹ In these patients, European and American expert committees agree that when high-risk heart conditions are specified in

these patients, it is essential to discuss with them, and eventually their cardiologists and/or surgeons, whether they should receive antibiotic prophylaxis for invasive periodontal procedures, including full periodontal examination, root surface debridement, and surgery.^{134,149,152}

5.3.3 | Aspiration pneumonia

Dysphagia (or difficulty in eating, drinking, or swallowing) has a prevalence of up to 16% in the general population.¹⁵³ Patients with dysphagia are at risk of aspiration, which may progress to pneumonia, which carries a significant risk of morbidity and mortality. There are multiple causes of dysphagia, including cerebral palsy, learning disability, stroke, and previous head and neck cancer therapy.¹⁵³⁻¹⁵⁵

Periodontitis represents a potential risk factor for the development of aspiration pneumonia in the elderly.¹⁵⁶ Dental plaque has been suggested as a risk factor for healthcare-associated pneumonia in patients who are hospitalized, with an increase in dental plaque levels with longer hospital stays.¹⁵⁷ Good oral hygiene is one of the most effective interventions in reducing the risk of aspiration pneumonia.¹⁵⁸ This includes toothbrushing and denture hygiene, as well as professional cleaning. In relation to toothbrushing, depending on the severity of dysphagia, it should be undertaken in an upright position using a nonfoaming toothpaste.^{154,159}

When delivering periodontal care, there are several strategies that can be implemented to reduce the risk of aspiration. Depending on the severity of dysphagia, patients may need to be kept in an upright or semisupine position of no more than 45° if the airway is compromised.^{154,155,159,160} The airway may be protected with a gauze trap.¹⁵⁵ In addition to frequent breaks during treatment, ultrasonic scalers should be used with caution with high volume suction.¹⁵⁴ It is important to note that some patients will be at risk of silent aspiration during procedures, without any signs or symptoms of protective reflexes.¹⁵⁵

5.3.4 | Blood-borne viruses

Patients who received inactivated blood products up to the 1990s may have contracted transfusion-transmitted infections, including HIV and hepatitis.^{127,161} This risk is increased in patients who are likely to have received transfusions multiple times, including transfusion-dependent thalassemia, sickle cell disease, hemophilia, and hematological malignancies.¹⁶² Complications of blood-borne viruses include liver disease and, depending on its severity, will have additional considerations for the management of this cohort.^{163,164} Current procedures for blood products with virus deactivation processes have reduced the prevalence of transfusion-related infections.¹⁶⁵ The transmission rate of hepatitis viruses to dental professionals is low and is concentrated in developing countries with a higher prevalence of hepatitis-infected individuals,¹⁶⁶ and probably in those who do not have direct access to antiviral agents that cure HIV infection in more than 95% of patients. The risk of HIV

transmission in the dental setting is also low, especially when rapid HIV testing of the source patient is available and, if necessary, access to postexposure prophylaxis.¹⁶⁷ Standard infection prevention and control procedures, careful history taking, appropriate immunization of the dental team, and sharps injury protocol should be in place to minimize the risk of transmission.¹⁶⁸ Applying these measures, periodontal treatment is effective in patients with virologically controlled HIV infection and can be performed safely in the dental clinic.¹⁶⁹ The potential complications of dental treatment of patients with viral hepatitis include the potential transmission of the infectious agent and those derived from hepatic dysfunction that favor the appearance of hemorrhages because of coagulation factor deficiency and requires restricting the prescription of hepatic metabolism drugs.¹⁷⁰

5.4 | Wound healing

Wound healing after periodontal therapy may be impaired in patients with medical comorbidities. For example, patients with poorly controlled diabetes mellitus are at an increased risk of delayed wound healing because of impaired immunity.^{27,28} The severity of the condition and related comorbidities should be assessed, and where appropriate by consulting with the medical team. Prior to invasive periodontal therapy, the blood glucose level should be measured using point-of-care tests meters for safe management.¹⁷¹ A determination of HbA1c (ie, glycated hemoglobin) performed in the last 3 months provides information on the degree of control of diabetes and indirectly on the risk of postoperative complications.⁵⁸ There is insufficient evidence to support the use of routine prophylactic antibiotics in patients with diabetes mellitus to reduce the risk of delayed healing and infection.^{136,172} The procedural site should be limited and healing monitored closely.¹⁷¹

The medical management of conditions may affect wound healing. For example, patients who have had radiotherapy to the head and neck region are at risk of osteoradionecrosis of the jaw. Schuurhuis et al¹⁷³ followed up patients who had dental assessment and treatment prior to radiotherapy for head and neck cancer over a 2-year period. Compromised extraction site healing was observed more frequently in patients who had periodontal pockets of ≥ 6 mm at the assessment prior to radiotherapy (19%) compared with those who had pockets of < 6 mm (4%). However, this was not statistically significant. Another study reported that the presence of severe periodontitis postoperatively had the strongest correlation for development of osteoradionecrosis.¹⁷⁴ Patients should have a detailed dental assessment prior to commencing cancer therapy to remove teeth with poor prognosis and severe periodontal involvement.⁹⁸ Maintenance of periodontal health postcancer therapy is essential in reducing the risk of compromised healing and the need for invasive procedures. When surgical periodontal procedures are indicated in areas of irradiated bone, these should be undertaken with caution after liaising with the patient's medical team.¹⁷⁵

Medications can impact wound healing after periodontal therapy. Among patients taking corticosteroids, immunosuppressants,

biologic agents, and disease-modifying antirheumatic drugs, there is a lack of delayed wound healing and medication-related osteonecrosis of the jaw.¹⁶¹ An association between medication-related osteonecrosis of the jaw and periodontitis has been described, although neither the direction of this association nor predisposing factors have been definitively clarified.⁸² Paradoxically, medication-related osteonecrosis of the jaw can occur following periodontal therapy,²⁴ although it is more commonly associated with dental extractions. Prevention is key in the management of medication-related osteonecrosis of the jaw, and a dental assessment should be undertaken prior to commencement of antiresorptive therapy.¹⁷⁶ For established areas of osteonecrosis, it should be managed conservatively, with symptomatic control and management of infections.^{176,177} The Faculty General Dental Practice (UK) guidelines¹³⁶ support the use of antibiotics when there is the presence of secondary infection. For extensive areas, surgery may be indicated.^{177,178}

In all patients who are medically compromised and at risk of delayed wound healing, a strict follow-up protocol should be in place. For instance, following invasive periodontal procedures, patients at risk of osteoradionecrosis or medication-related osteonecrosis of the jaw should be reviewed to assess the healing.^{98,176} In addition, a regular recall interval is essential in maintaining their oral health and reducing the risk of complications.^{176,178} This should be agreed for individual patients.¹⁷⁹

6 | CONCLUSIONS

A complication in medicine is an unanticipated problem that arises following, and is a result of, a procedure, treatment, or illness. Complications may adversely affect the prognosis or outcome of a disease. On the other hand, errors are part of our professional lives. Dentists, as well as physicians, are prone to errors in their profession that can impact on their patients' health and quality of life. The main difference between an adverse event and a complication is that the former is the consequence of a treatment while the latter is a consequence of the disease process.

In this review we have summarized the most common complications reported in patients with systemic comorbidities undergoing periodontal therapy. A framework for risk assessment was provided, including aspects of preoperative planning and intraoperative performance, which we hope will help colleagues prevent and minimize the incidence of treatment complications.

ACKNOWLEDGMENTS

Yago Leira held a Senior Clinical Research Fellowship supported by the UCL Biomedical Research Centre (NIHR-INF-0387) and a research contract with Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS). Marco Orlandi was a NIHR Clinical Lecturer and Hana Cho held an NIHR Academic Clinical Fellowship. All the authors work at UCL/UCLH, which receives funding from the NIHR.

FUNDING INFORMATION

This review was self-funded.

CONFLICT OF INTEREST

The authors report no conflict of interest in connection with this review.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available because of privacy or ethical restrictions.

ORCID

Yago Leira  <https://orcid.org/0000-0001-5027-7276>

REFERENCES

1. United Nations, Department of Economic and Social Affairs, Population Division. *World Population Prospects 2019*; 2019. <https://population.un.org/wpp/>. Accessed October 14, 2020.
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):1789-1858.
3. Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. *PLoS One*. 2014;9(7):e102149.
4. Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. *Ageing Res Rev*. 2011;10(4):430-439.
5. Brasher WJ, Rees TD. Systemic conditions in the management of periodontal patients. *J Periodontol*. 1970;41(6):349-352.
6. Rees TD, Brasher WJ. Incidence of certain systemic conditions among patients presenting for periodontal treatment. *J Periodontol*. 1974;45(9):669-671.
7. Peacock ME, Carson RE. Frequency of self-reported medical conditions in periodontal patients. *J Periodontol*. 1995;66(11):1004-1007.
8. Nery EB, Meister F Jr, Ellinger RF, Eslami A, McNamara TJ. Prevalence of medical problems in periodontal patients obtained from three different populations. *J Periodontol*. 1987;58(8):564-568.
9. Dhanuthai K, Sappayatosok K, Bijaphala P, Kulvitit S, Sereerat T. Prevalence of medically compromised conditions in dental patients. *Med Oral Patol Oral Cir Bucal*. 2009;14(6):E287-E291.
10. Frydrych AM, Parsons R, Kujan O. Medical status of patients presenting for treatment at an Australian dental institute: a cross-sectional study. *BMC Oral Health*. 2020;20(1):289.
11. Radfar L, Suresh L. Medical profile of a dental school patient population. *J Dent Educ*. 2007;71(5):682-686.
12. Ferreira R, Michel RC, Gregghi SL, et al. Prevention and periodontal treatment in down syndrome patients: a systematic review. *PLoS One*. 2016;11(6):e0158339.
13. Hanisch M, Hoffmann T, Bohner L, et al. Rare diseases with periodontal manifestations. *Int J Environ Res Public Health*. 2019;16(5):1-19.
14. Askar H, Di Gianfilippo R, Ravida A, Tattan M, Majzoub J, Wang HL. Incidence and severity of postoperative complications following oral, periodontal, and implant surgeries: a retrospective study. *J Periodontol*. 2019;90(11):1270-1278.

15. Griffin TJ, Cheung WS, Zavras AI, Damoulis PD. Postoperative complications following gingival augmentation procedures. *J Periodontol*. 2006;77(12):2070-2079.
16. Curtis JW Jr, McLain JB, Hutchinson RA. The incidence and severity of complications and pain following periodontal surgery. *J Periodontol*. 1985;56(10):597-601.
17. Mei CC, Lee FY, Yeh HC. Assessment of pain perception following periodontal and implant surgeries. *J Clin Periodontol*. 2016;43(12):1151-1159.
18. Pack PD, Haber J. The incidence of clinical infection after periodontal surgery. A retrospective study. *J Periodontol*. 1983;54(7):441-443.
19. Checchi L, Trombelli L, Nonato M. Postoperative infections and tetracycline prophylaxis in periodontal surgery: a retrospective study. *Quintessence Int*. 1992;23(3):191-195.
20. Powell CA, Mealey BL, Deas DE, McDonnell HT, Moritz AJ. Post-surgical infections: prevalence associated with various periodontal surgical procedures. *J Periodontol*. 2005;76(3):329-333.
21. Andersen KM, Selvig KA, Leknes KN. Altered healing following mucogingival surgery in a patient with Crohn's disease: a literature review and case report. *J Periodontol*. 2003;74(4):537-546.
22. Blanco-Carrion J, Linares-Gonzalez A, Batalla-Vazquez P, Diz-Dios P. Morbidity and economic complications following mucogingival surgery in a hemophilic HIV-infected patient: a case report. *J Periodontol*. 2004;75(10):1413-1416.
23. Cutler CW, Eke P, Arnold RR, Van Dyke TE. Defective neutrophil function in an insulin-dependent diabetes mellitus patients. A case report. *J Periodontol*. 1991;62(6):394-401.
24. Diniz-Freitas M, Fernandez-Feijoo J, Diz Dios P, Pousa X, Limeres J. Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: a case report. *J Clin Periodontol*. 2018;45(5):570-577.
25. Elad S, Chackartchi T, Shapira L, Findler M. A critically severe gingival bleeding following non-surgical periodontal treatment in patients medicated with anti-platelet. *J Clin Periodontol*. 2008;35(4):342-345.
26. Knapp JF, Fiori T. Oral hemorrhage associated with periodontal surgery and hypertensive crisis. *J Am Dent Assoc*. 1984;108(1):49-51.
27. Mattson JS, Gallagher SJ, Jabro MH, McLey LL. Complications associated with diabetes mellitus after guided tissue regeneration: case report. *Compend Contin Educ Dent*. 1998;19(9):923-926. 8, 30 passim; quiz 38.
28. Mullally BH, Linden GJ, Napier SS. Candidal infection as a complication of barrier membrane placement in a diabetic patient. *J Dent Assoc*. 1993;39(4):86-88.
29. Nishide N, Nishikawa T, Kanamura N. Extensive bleeding during surgical treatment for gingival overgrowth in a patient on haemodialysis – a case report and review of the literature. *Aust Dent J*. 2005;50(4):276-281.
30. Scheitler LE, Hart N, Phillips G, Weinberg JB. Hematologic and surgical management of the dental patient with plasminogen activator deficiency. *Oral Surg Oral Med Oral Pathol*. 1988;66(6):680-682.
31. Shapiro N. When the bleeding won't stop: a case report on a patient with hemophilia. *J Am Dent Assoc*. 1993;124(12):64-67.
32. Thomason JM, Seymour RA, Murphy P, Brigham KM, Jones P. Aspirin-induced post-gingivectomy haemorrhage: a timely reminder. *J Clin Periodontol*. 1997;24(2):136-138.
33. Gregoriou AP, Schneider PE, Shaw PR. Phenobarbital-induced gingival overgrowth? Report of two cases and complications in management. *ASDC J Dent Child*. 1996;63(6):408-413.
34. Jones JE, Weddell JA, McKown CG. Incidence and indications for surgical management of phenytoin-induced gingival overgrowth in a cerebral palsy population. *J Oral Maxillofac Surg*. 1988;46(5):385-390.
35. Campo J, Cano J, del Romero J, Hernando V, Rodriguez C, Bascones A. Oral complication risks after invasive and non-invasive dental procedures in HIV-positive patients. *Oral Dis*. 2007;13(1):110-116.
36. Deppe H, Mucke T, Auer-Bahrs J, Wagenpfeil S, Kesting M, Sculean A. Bleeding complications following Nd:YAG laser-assisted oral surgery vs conventional treatment in cardiac risk patients: a clinical retrospective comparative study. *Quintessence Int*. 2013;44(7):513-520.
37. Federici AB, Sacco R, Stabile F, Carpenedo M, Zingaro E, Mannucci PM. Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases. *Haemophilia*. 2000;6(2):71-77.
38. Franchini M, Rossetti G, Tagliaferri A, et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers. *Haemophilia*. 2005;11(5):504-509.
39. D'Aiuto F, Gkraniias N, Bhowruth D, et al. Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. *Lancet Diabetes Endocrinol*. 2018;6(12):954-965.
40. Lee AP, Boyle CA, Savidge GF, Fiske J. Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash. *Br Dent J*. 2005;198(1):33-8; discussion 26.
41. Vassilopoulos P, Palcanis K. Bleeding disorders and periodontology. *Periodontol 2000*. 2007;44:211-223.
42. Nickles K, Wohlfeil M, Alesci S, Miesbach W, Eickholz P. Comprehensive treatment of periodontitis in patients with von Willebrand disease. *J Periodontol*. 2010;81(10):1432-1440.
43. Petrover MG, Cohen CI. The use of desmopressin in the management of two patients with von Willebrand's disease undergoing periodontal surgery. 2 case reports. *J Periodontol*. 1990;61(4):239-242.
44. Austin GB, Quart AM, Novak B. Hereditary hemorrhagic telangiectasia with oral manifestations. Report of periodontal treatment in two cases. *Oral Surg Oral Med Oral Pathol*. 1981;51(3):245-251.
45. Hughes FJ, Bartold PM. Periodontal complications of prescription and recreational drugs. *Periodontol 2000*. 2018;78(1):47-58.
46. Bhansali RS, Yeltiwar RK, Agrawal AA. Periodontal management of gingival enlargement associated with Sturge-Weber syndrome. *J Periodontol*. 2008;79(3):549-555.
47. Capodiferro S, Tempesta A, Limongelli L, Maiorano E, Benedicenti S, Favia G. Nonsurgical periodontal treatment by Erbium:YAG laser promotes regression of gingival overgrowth in patient taking cyclosporine A: a case report. *Photobiomodul Photomed Laser Surg*. 2019;37(1):53-56.
48. Kolhatkar S, Haque SA, Winkler JR, Bhola M. Root coverage in an HIV-positive individual: combined use of a lateral sliding flap and resin-modified glass ionomer for the management of an isolated severe recession defect. *J Periodontol*. 2010;81(4):632-640.
49. Kolhatkar S, Mason SA, Janic A, Bhola M, Haque S, Winkler JR. Surgical crown lengthening in a population with human immunodeficiency virus: a retrospective analysis. *J Periodontol*. 2012;83(3):344-353.
50. Brain JH, Paul BF, Assad DA. Periodontal plastic surgery in a dystrophic epidermolysis bullosa patient: review and case report. *J Periodontol*. 1999;70(11):1392-1396.
51. Buduneli E, Ilgenli T, Buduneli N, Ozdemir F. Acellular dermal matrix allograft used to gain attached gingiva in a case of epidermolysis bullosa. *J Clin Periodontol*. 2003;30(11):1011-1015.
52. Scully C. *Scully's Medical Problems in Dentistry*. 7th ed. Churchill; 2014.

53. Dougall A, Fiske J. Access to special care dentistry, part 1. *Access. Br Dent J.* 2008;204(11):605-616.
54. Mitakides J, Tinkle BT. Oral and mandibular manifestations in the Ehlers-Danlos syndromes. *Am J Med Genet C Semin Med Genet.* 2017;175(1):220-225.
55. Becker DE, Reed KL. Local anesthetics: review of pharmacological considerations. *Anesth Prog.* 2012;59(2):90-101. quiz 2-3.
56. Schubart JR, Schaefer E, Janicki P, et al. Resistance to local anesthesia in people with the Ehlers-Danlos Syndromes presenting for dental surgery. *J Dent Anesth Pain Med.* 2019;19(5):261-270.
57. Bina B, Hersh EV, Hilario M, Alvarez K, McLaughlin B. True allergy to amide local anesthetics: a review and case presentation. *Anesth Prog.* 2018;65(2):119-123.
58. Scully C, Diz Dios P, Kumar N. *Special Care in Dentistry.* Churchill Livingstone; 2007.
59. Tomoyasu Y, Mukae K, Suda M, et al. Allergic reactions to local anesthetics in dental patients: analysis of intracutaneous and challenge tests. *Open Dent J.* 2011;5:146-149.
60. Sambrook PJ, Goss AN. Severe adverse reactions to dental local anaesthetics: prolonged mandibular and lingual nerve anaesthesia. *Aust Dent J.* 2011;56(2):154-159.
61. Serrera Figallo MA, Velazquez Cayon RT, Torres Lagares D, Corcuera Flores JR, Machuca PG. Use of anesthetics associated to vasoconstrictors for dentistry in patients with cardiopathies. Review of the literature published in the last decade. *J Clin Exp Dent.* 2012;4(2):e107-e111.
62. Hashemian AM, Omraninava A, Kakhki AD, et al. Effectiveness of local anesthesia with lidocaine in chronic opium abusers. *J Emerg Trauma Shock.* 2014;7(4):301-304.
63. Anderson JA, Brewer A, Creagh D, et al. Guidance on the dental management of patients with haemophilia and congenital bleeding disorders. *Br Dent J.* 2013;215(10):497-504.
64. Dougall A, Apperley O, Smith G, Madden L, Parkinson L, Daly B. Safety of buccal infiltration local anaesthesia for dental procedures. *Haemophilia.* 2019;25(2):270-275.
65. Perry DJ, Noakes TJ, Helliwell PS, British Dental Society. Guidelines for the management of patients on oral anticoagulants requiring dental surgery. *Br Dent J.* 2007;203(7):389-393.
66. Scottish Dental Clinical Effectiveness Programme (SDCEP). *Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs.* 2nd ed. SDCEP; 2022.
67. Meechan JG. How to overcome failed local anaesthesia. *Br Dent J.* 1999;186(1):15-20.
68. Goldberg S, Reader A, Drum M, Nusstein J, Beck M. Comparison of the anesthetic efficacy of the conventional inferior alveolar, Gow-Gates, and Vazirani-Akinosi techniques. *J Endod.* 2008;34(11):1306-1311.
69. Nagendrababu V, Aly Ahmed HM, Pulikkotil SJ, Veettil SK, Dharmarajan L, Setzer FC. Anesthetic efficacy of Gow-Gates, Vazirani-Akinosi, and mental incisive nerve blocks for treatment of symptomatic irreversible pulpitis: a systematic review and meta-analysis with trial sequential analysis. *J Endod.* 2019;45(10):1175-83 e3.
70. Moore PA, Cuddy MA, Cooke MR, Sokolowski CJ. Periodontal ligament and intraosseous anesthetic injection techniques: alternatives to mandibular nerve blocks. *J Am Dent Assoc.* 2011;142(Suppl 3):135-185.
71. Kwak EJ, Pang NS, Cho JH, Jung BY, Kim KD, Park W. Computer-controlled local anesthetic delivery for painless anesthesia: a literature review. *J Dent Anesth Pain Med.* 2016;16(2):81-88.
72. Angelo Z, Polyvios C. Alternative practices of achieving anaesthesia for dental procedures: a review. *J Dent Anesth Pain Med.* 2018;18(2):79-88.
73. Aggarwal K, Lamba AK, Faraz F, Tandon S, Makker K. Comparison of anxiety and pain perceived with conventional and computerized local anesthesia delivery systems for different stages of anesthesia delivery in maxillary and mandibular nerve blocks. *J Dent Anesth Pain Med.* 2018;18(6):367-373.
74. Han K, Kim J. Intraosseous anesthesia using a computer-controlled system during non-surgical periodontal therapy (root planing): two case reports. *J Dent Anesth Pain Med.* 2018;18(1):65-69.
75. Chang H, Noh J, Lee J, et al. Relief of injection pain during delivery of local anesthesia by computer-controlled anesthetic delivery system for periodontal surgery: randomized clinical controlled trial. *J Periodontol.* 2016;87(7):783-789.
76. Boronat Lopez A, Penarrocha DM. Failure of locoregional anesthesia in dental practice. Review of the literature. *Med Oral Patol Oral Cir Bucal.* 2006;11(6):E510-E513.
77. Kramer SM, Serrano MC, Zillmann G, et al. Oral health care for patients with epidermolysis bullosa – best clinical practice guidelines. *Int J Paediatr Dent.* 2012;22(Suppl 1):1-35.
78. Siqueira MA, de Souza SJ, Silva FW, Diaz-Serrano KV, Freitas AC, Queiroz AM. Dental treatment in a patient with epidermolysis bullosa. *Spec Care Dentist.* 2008;28(3):92-95.
79. Canakci CF, Canakci V. Pain experienced by patients undergoing different periodontal therapies. *J Am Dent Assoc.* 2007;138(12):1563-1573.
80. Aslund M, Suvan J, Moles DR, D'Aiuto F, Tonetti MS. Effects of two different methods of non-surgical periodontal therapy on patient perception of pain and quality of life: a randomized controlled clinical trial. *J Periodontol.* 2008;79(6):1031-1040.
81. Moore PA, Hersh EV. Analgesic therapy in dentistry: from a letter to the editor to an evidence-base review. *Dent Clin North Am.* 2019;63(1):35-44.
82. Lorenzo-Pouso AI, Perez-Sayans M, Chamorro-Petronacci C, et al. Association between periodontitis and medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. *J Oral Pathol Med.* 2020;49(3):190-200.
83. Guggenheimer J, Moore PA. The therapeutic applications of and risks associated with acetaminophen use: a review and update. *J Am Dent Assoc.* 2011;142(1):38-44.
84. Hersh EV, Moore PA. Three serious drug interactions that every dentist should know about. *Compend Contin Educ Dent.* 2015;36(6):408-413. quiz 14, 16.
85. Steffens JP, Santos FA, Pilatti GL. The use of etoricoxib and celecoxib for pain prevention after periodontal surgery: a double-masked, parallel-group, placebo-controlled, randomized clinical trial. *J Periodontol.* 2011;82(9):1238-1244.
86. Pilatti GL, Andre dos Santos F, Bianchi A, Cavassim R, Tozetto CW. The use of celecoxib and dexamethasone for the prevention and control of postoperative pain after periodontal surgery. *J Periodontol.* 2006;77(11):1809-1814.
87. Arora M, Choudhary S, Singh PK, Sapra B, Silakari O. Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: a review. *Life Sci.* 2020;251:117631.
88. Donati M, Conforti A, Lenti MC, et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. *Br J Clin Pharmacol.* 2016;82(1):238-248.
89. Hewson ID, Daly J, Hallett KB, et al. Consensus statement by hospital based dentists providing dental treatment for patients with inherited bleeding disorders. *Aust Dent J.* 2011;56(2):221-226.
90. Weycker D, Hatfield M, Grossman A, et al. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. *BMC Cancer.* 2019;19(1):151.
91. Rafique S, Fiske J, Palmer G, Daly B. Special care dentistry: part 1. Dental management of patients with inherited bleeding disorders. *Dent Update.* 2013;40(8):613-616. 9-22, 25-6 passim.
92. Lockhart PB, Gibson J, Pond SH, Leitch J. Dental management considerations for the patient with an acquired coagulopathy. Part 2: coagulopathies from drugs. *Br Dent J.* 2003;195(9):495-501.

93. Bell AD, Roussin A, Cartier R, et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. *Can J Cardiol.* 2011;27(Suppl A):S1-S59.
94. Brewer A, Elvira Correa M. *Guidelines for Dental Treatment of Patients with Inherited Bleeding Disorders.* World Federation of Hemophilia; 2006.
95. World Federation of Hemophilia, ed. *Guidelines for the Management of Haemophilia.* 2nd ed. World Federation of Hemophilia; 2012.
96. Constantinides F, Castronovo G, Vettori E, et al. Dental care for patients with end-stage renal disease and undergoing hemodialysis. *Int J Dent.* 2018;2018:9610892.
97. Morimoto Y, Niwa H, Minematsu K. Hemostatic management for periodontal treatments in patients on oral antithrombotic therapy: a retrospective study. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2009;108(6):889-896.
98. Royal College of Surgeons of England (RCS Eng)/British Society for Disability and Oral Health (BSDH). *The Oral Management of Oncology Patients Requiring Radiotherapy, Chemotherapy and/or Bone Marrow Transplantation: Clinical Guidelines.* RCS Eng/BSDH; 2018.
99. Lockhart PB, Gibson J, Pond SH, Leitch J. Dental management considerations for the patient with an acquired coagulopathy. Part 1: coagulopathies from systemic disease. *Br Dent J.* 2003;195(8):439-445.
100. Karasneh J, Christoforou J, Walker JS, Dios PD, Lockhart PB, Patton LL. World Workshop on Oral Medicine VII: bleeding control interventions for invasive dental procedures in patients with inherited functional platelet disorders: a systematic review. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2022;133(4):412-431.
101. Sandhu S, Sankar V, Villa A. Bleeding risk in thrombocytopenic patients after dental extractions: a retrospective single-center study. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2020;129(5):478-483.
102. Kantarci A, Cebeci I, Firatli E, Atamer T, Tuncer O. Periodontal management of Glanzmann's thrombasthenia: report of 3 cases. *J Periodontol.* 1996;67(8):816-820.
103. Estcourt LJ, Birchall J, Allard S, et al. Guidelines for the use of platelet transfusions. *Br J Haematol.* 2017;176(3):365-394.
104. Zimmermann C, Meurer MI, Grando LJ, Gonzaga Del Moral JA, da Silva Rath IB, Schaefer TS. Dental treatment in patients with leukemia. *J Oncol.* 2015;2015:571739.
105. Padron N, Limeres J, Tomas I, Diz DP. Oral health and health behavior in patients under anticoagulation therapy. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2003;96(5):519-520.
106. Shastry SP, Kaul R, Baroudi K, Umar D. Hemophilia A: dental considerations and management. *J Int Soc Prev Community Dent.* 2014;4(Suppl 3):S147-S152.
107. Kalsi H, Nanayakkara L, Pasi KJ, Bowles L, Hart DP. Access to primary dental care for patients with inherited bleeding disorders. *Haemophilia.* 2012;18(4):510-515.
108. Vinall C, Stassen LF. The dental patient with a congenital bleeding disorder. *J Ir Dent Assoc.* 2008;54(1):24-28.
109. Smith GDA. To audit the success rate using 4% articaine as buccal infiltration in order to anaesthetise mandibular molars for restorative dental treatment in patients with a hereditary coagulation disorder. *Haemophilia.* 2010;16:51.
110. Meehan JG. Infiltration anesthesia in the mandible. *Dent Clin North Am.* 2010;54(4):621-629.
111. Robertson D, Nusstein J, Reader A, Beck M, McCartney M. The anesthetic efficacy of articaine in buccal infiltration of mandibular posterior teeth. *J Am Dent Assoc.* 2007;138(8):1104-1112.
112. Gupta A, Epstein JB, Cabay RJ. Bleeding disorders of importance in dental care and related patient management. *J Can Dent Assoc.* 2007;73(1):77-83.
113. Dougall A, Fiske J. Access to special care dentistry, part 5. Safety. *Br Dent J.* 2008;205(4):177-190.
114. Israels S, Schwetz N, Boyar R, McNicol A. Bleeding disorders: characterization, dental considerations and management. *J Can Dent Assoc.* 2006;72(9):827.
115. Rubino RT, Dawson DR 3rd, Kryscio RJ, Al-Sabbagh M, Miller CS. Postoperative bleeding associated with antiplatelet and anticoagulant drugs: a retrospective study. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2019;128(3):243-249.
116. Carter G, Goss A. Tranexamic acid mouthwash – a prospective randomized study of a 2-day regimen vs 5-day regimen to prevent postoperative bleeding in anticoagulated patients requiring dental extractions. *Int J Oral Maxillofac Surg.* 2003;32(5):504-507.
117. Engelen ET, Schutgens RE, Mauser-Bunschoten EP, van Es RJ, van Galen KP. Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions. *Cochrane Database Syst Rev.* 2018;7(7):CD012293.
118. van Galen KP, Engelen ET, Mauser-Bunschoten EP, van Es RJ, Schutgens RE. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. *Cochrane Database Syst Rev.* 2019;4(4):CD011385.
119. Jover Cerveró A, Bagán JV, Jiménez Soriano Y, Poveda Roda R. Dental management in renal failure: patients on dialysis. *Med Oral Patol Oral Cir Bucal.* 2008;13(7):E419-E426.
120. López BC, Esteve CG, Pérez MGS. Dental treatment considerations in the chemotherapy patient. *J Clin Exp Dent.* 2011;3:e31-e42.
121. Pouloupoulos AP, Padadopoulos P, Andreadis D. Chemotherapy: oral side effects and dental interventions – a review of the literature. *Stomatological Dis Sci.* 2017;1:35-49.
122. Raber-Durlacher JE, Epstein JB, Raber J, et al. Periodontal infection in cancer patients treated with high-dose chemotherapy. *Support Care Cancer.* 2002;10(6):466-473.
123. Georgakopoulou EA, Ahtari MD, Afentoulide N. Dental management of patients before and after renal transplantation. *Stomatologija.* 2011;13(4):107-112.
124. Panagiota-Alexia M, Nikos K, Anni G, Lambros Z. Dental management of patients with liver transplant. *EC Dent Sci.* 2017;14:41-49.
125. Fabuel L, Gavalda Esteve C, Pérez MGS. Dental management in transplant patients. *J Clin Exp Dent.* 2011;3(1):e43-e52.
126. Kwak EJ, Kim DJ, Choi Y, Joo DJ, Park W. Importance of oral health and dental treatment in organ transplant recipients. *Int Dent J.* 2020;70(6):477-481.
127. Cappellni MD, Cohen A, Porter J, Taher A, Viprakasit V. *Guidelines for the Management of Transfusion Dependent Thalassaemia.* 3rd ed. Thalassaemia International Federation; 2014.
128. Chekroun M, Cherifi H, Fournier B, et al. Oral manifestations of sickle cell disease. *Br Dent J.* 2019;226(1):27-31.
129. Fillmore WJ, Leavitt BD, Arce K. Dental extraction in the neutropenic patient. *J Oral Maxillofac Surg.* 2014;72(12):2386-2393.
130. Squire JD, Gardner PJ, Moutsopoulos NM, Leiding JW. Antibiotic prophylaxis for dental treatment in patients with immunodeficiency. *J Allergy Clin Immunol Pract.* 2019;7(3):819-823.
131. Helmi N, Bashir M, Shireen A, Ahmed IM. Thalassaemia review: features, dental considerations and management. *Electron Physician.* 2017;9(3):4003-4008.
132. Sickel Cell Society. *Standards for the Clinical Care of Adults With Sickel Cell Disease in the UK.* Sickel Cell Society; 2018.
133. American Academy of Pediatric Dentistry. Dental management of pediatric patients receiving immunosuppressive therapy and/or radiation therapy. *The Reference Manual of Pediatric Dentistry.* American Academy of Pediatric Dentistry; 2020:453-461.
134. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on

- Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation*. 2007;116(15):1736-1754.
135. Joint Formulary Committee. *Prescribing in Dental Practice: General Guidance*. Joint Formulary Committee: British National Formulary. <https://bnf.nice.org.uk/guidance/prescribing-in-dental-practice.html>. Accessed November 10, 2020.
 136. Faculty of General Dental Practice (UK)/Faculty of Dental Surgery (FDS). *Antimicrobial Prescribing in Dentistry: Good Practice Guidelines*. 3rd ed. Faculty of General Dental Practice (UK); 2020.
 137. Khalaf MW, Khader R, Cobetto G, Yepes JF, Karounos DG, Miller CS. Risk of adrenal crisis in dental patients: results of a systematic search of the literature. *J Am Dent Assoc*. 2013;144(2):152-160.
 138. Nicholson G, Burrin JM, Hall GM. Peri-operative steroid supplementation. *Anaesthesia*. 1998;53(11):1091-1104.
 139. Gibson N, Ferguson JW. Steroid cover for dental patients on long-term steroid medication: proposed clinical guidelines based upon a critical review of the literature. *Br Dent J*. 2004;197(11):681-685.
 140. King R, Zebic L, Patel V. Deciphering novel chemotherapy and its impact on dentistry. *Br Dent J*. 2020;228(6):415-421.
 141. National Institute for Health and Clinical Excellence: Guidance. *Prophylaxis Against Infective Endocarditis: Antimicrobial Prophylaxis Against Infective Endocarditis in Adults and Children Undergoing Interventional Procedures*. Vol 64. National Institute for Health and Care Excellence Guideline Clinical Guideline; 2008.
 142. Dhotre S, Jahagirdar V, Suryawanshi N, Davane M, Patil R, Nagoba B. Assessment of periodontitis and its role in viridans streptococcal bacteremia and infective endocarditis. *Indian Heart J*. 2018;70(2):225-232.
 143. Carinci F, Martinelli M, Contaldo M, et al. Focus on periodontal disease and development of endocarditis. *J Biol Regul Homeost Agents*. 2018;32(2 Suppl. 1):143-147.
 144. Nakano K, Nemoto H, Nomura R, et al. Detection of oral bacteria in cardiovascular specimens. *Oral Microbiol Immunol*. 2009;24(1):64-68.
 145. Marin MJ, Ambrosio N, Virto L, et al. Detection and quantification of *Aggregatibacter actinomycetemcomitans*, *Porphyromonas gingivalis* and *Streptococcus oralis* in blood samples with different microbiological identification methods: an in vitro study. *Arch Oral Biol*. 2017;74:55-62.
 146. Martin M. Is there a link between tooth brushing and infective endocarditis? *Int Dent J*. 2003;53(Suppl 3):187-190.
 147. Lockhart PB, Brennan MT, Thornhill M, et al. Poor oral hygiene as a risk factor for infective endocarditis-related bacteremia. *J Am Dent Assoc*. 2009;140(10):1238-1244.
 148. Lockhart PB, Brennan MT, Sasser HC, Fox PC, Paster BJ, Bahrani-Mougeot FK. Bacteremia associated with toothbrushing and dental extraction. *Circulation*. 2008;117(24):3118-3125.
 149. Scottish Dental Clinical Effectiveness Programme (SDCEP). *Antibiotic Prophylaxis Against Infective Endocarditis Implementation Advice*. SDCEP; 2018.
 150. Seymour RA, Preshaw PM, Thomason JM, Ellis JS, Steele JG. Cardiovascular diseases and periodontology. *J Clin Periodontol*. 2003;30(4):279-292.
 151. Mutzbauer TS, Imfeld T. Präventiver und therapeutischer Einsatz von Antibiotika in der Zahnheilkunde. *Ther Umsch*. 2008;65(2):115-119.
 152. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). *Eur Heart J*. 2015;36(44):3075-3128.
 153. Public Health England. *Health Inequalities: Dysphagia*. 2014;41(5):413-416. 9-20, 22.
 154. Curl C, Boyle C. Dysphagia and dentistry. *Dent Update*. 2014;41(5):413-416. 9-20, 22.
 155. Quek HC, Lee YS. Dentistry considerations for the dysphagic patient: recognition of condition and management. *Proc Singapore Healthc*. 2019;28(4):288-292.
 156. Terpenning MS, Taylor GW, Lopatin DE, Kerr CK, Dominguez BL, Loesche WJ. Aspiration pneumonia: dental and oral risk factors in an older veteran population. *J Am Geriatr Soc*. 2001;49(5):557-563.
 157. Sachdev M, Ready D, Brealey D, et al. Changes in dental plaque following hospitalisation in a critical care unit: an observational study. *Crit Care*. 2013;17(5):R189.
 158. Tay WYLL, Tan SY, Vasanthwala FF. Evidence-based measures for preventing aspiration pneumonia in patients with dysphagia. *Proc Singapore Healthc*. 2014;23(2):158-165.
 159. British Society of Gerodontology. *Guidelines for the Oral Healthcare of Stroke Survivors*. British Society of Gerodontology; 2010.
 160. Doughty J, Cho H, Kumar N. The gastric pacemaker and its implications for dental treatment. *JDOH*. 2017;18(4):132-137.
 161. Hayashi M, Morimoto Y, Iida T, Tanaka Y, Sugiyama S. Risk of delayed healing of tooth extraction wounds and osteonecrosis of the jaw among patients treated with potential immunosuppressive drugs: a retrospective cohort study. *Tohoku J Exp Med*. 2018;246(4):257-264.
 162. Ainley LI, Hewitt PE. Haematology patients and the risk of transfusion transmitted infection. *Br J Haematol*. 2018;180(4):473-483.
 163. Prati D. Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major. *Vox Sang*. 2000;79(3):129-137.
 164. Lambing A, Kuriakose P, Kachalsky E. Liver transplantation in the haemophilia patient. *Haemophilia*. 2012;18(2):300-303.
 165. Kucharska M, Ingot M, Szymczak A, et al. Co-infection of the hepatitis C virus with other blood-borne and hepatotropic viruses among hemophilia patients in Poland. *Hepat Mon*. 2016;16(9):e35658.
 166. Mahboobi N, Porter SR, Karayiannis P, Alavian SM. Dental treatment as a risk factor for hepatitis B and C viral infection. A review of the recent literature. *J Gastrointest Liver Dis*. 2013;22(1):79-86.
 167. Cleveland JL, Barker L, Gooch BF, et al. Use of HIV postexposure prophylaxis by dental health care personnel: an overview and updated recommendations. *J Am Dent Assoc*. 2002;133(12):1619-1626.
 168. Lala R, Harwood C, Eapen Simon S, Lee A, Jones K. Blood borne viruses – key facts for primary care dental teams. *BDJ Team*. 2018;5:18075.
 169. Jordan RA, Lucaci A, Schaper K, Jöhren HP, Zimmer S. Effectiveness of systematic periodontal treatment in male HIV-infected patients after 9 years: a case series. *Adv Med*. 2018;2018:4135607.
 170. Klevens RM, Moorman AC. Hepatitis C virus: an overview for dental health care providers. *J Am Dent Assoc*. 2013;144(12):1340-1347.
 171. Lewis D, Fiske J, Dougall A. Access to special care dentistry, part 7. Special care dentistry services: seamless care for people in their middle years – part 1. *Br Dent J*. 2008;205(6):305-317.
 172. Nayani S, Mustafa OG. Management of diabetes in people undergoing dental treatment in primary care. *Prim Dent J*. 2020;9(2):38-46.
 173. Schuurhuis JM, Stokman MA, Witjes MJH, et al. Patients with advanced periodontal disease before intensity-modulated radiation therapy are prone to develop bone healing problems: a 2-year prospective follow-up study. *Support Care Cancer*. 2018;26(4):1133-1142.
 174. Katsura K, Sasai K, Sato K, Saito M, Hoshina H, Hayashi T. Relationship between oral health status and development of osteoradionecrosis of the mandible: a retrospective longitudinal study. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2008;105(6):731-738.

175. Irie MS, Mendes EM, Borges JS, Osuna LG, Rabelo GD, Soares PB. Periodontal therapy for patients before and after radiotherapy: a review of the literature and topics of interest for clinicians. *Med Oral Patol Oral Cir Bucal*. 2018;23(5):e524-e530.
176. Scottish Dental Clinical Effectiveness Programme (SDCEP). *Oral Health Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw*. SDCEP; 2017.
177. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw – 2014 update. *J Oral Maxillofac Surg*. 2014;72(10):1938-1956.
178. He L, Sun X, Liu Z, Qiu Y, Niu Y. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. *Int J Oral Sci*. 2020;12(1):30.
179. National Institute for Health and Care Excellence. *Dental Checks: Intervals Between Oral Health Reviews*. National Institute for Health and Care Excellence Clinical Guideline 19; 2004.

How to cite this article: Leira Y, Cho H, Marletta D, et al. Complications and treatment errors in periodontal therapy in medically compromised patients. *Periodontol 2000*. 2023;92:197-219. doi: [10.1111/prd.12444](https://doi.org/10.1111/prd.12444)